ERLEADA (apalutamide) tablets, for oral use. Initial U.S. Approval – 2018

Category: .

ERLEADA (apalutamide) tablets, for oral use. Initial U.S. Approval – 2018

ERLEADA 240 mg (four 60 mg tablets) administered orally once daily. Swallow tablets whole. ERLEADA can be taken with or without food. Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.
Tablets: 60 mg
Manufactured By: Janssen Products, LP
Prescribing Information URL: Click Here

Access to ERLEADA ™ (apalutamide) tablets: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Apalutamide, sold under the brand name Erleada among others, is a nonsteroidal antiandrogen (NSAA) medication which is used in the treatment of prostate cancer. It is specifically indicated for use in conjunction with castration in the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC).
Apalutamide was first described in 2007, and was approved for the treatment of prostate cancer in February 2018. It was the first medication to be approved specifically for the treatment of NM-CRPC.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.